The stock of Lexeo Therapeutics Inc (LXEO) has seen a -32.01% decrease in the past week, with a -37.70% drop in the past month, and a -50.62% decrease in the past quarter. The volatility ratio for the week is 15.38%, and the volatility levels for the past 30 days are at 11.78% for LXEO. The simple moving average for the past 20 days is -24.39% for LXEO’s stock, with a -62.30% simple moving average for the past 200 days.
Is It Worth Investing in Lexeo Therapeutics Inc (NASDAQ: LXEO) Right Now?
The stock has a 36-month beta value of 3.17. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LXEO is 23.54M, and at present, short sellers hold a 7.98% of that float. On February 13, 2025, the average trading volume of LXEO was 362.86K shares.
LXEO) stock’s latest price update
Lexeo Therapeutics Inc (NASDAQ: LXEO)’s stock price has gone decline by -7.06 in comparison to its previous close of 4.25, however, the company has experienced a -32.01% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-01-07 that NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P.
Analysts’ Opinion of LXEO
Many brokerage firms have already submitted their reports for LXEO stocks, with Robert W. Baird repeating the rating for LXEO by listing it as a “Outperform.” The predicted price for LXEO in the upcoming period, according to Robert W. Baird is $28 based on the research report published on June 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXEO reach a price target of $22. The rating they have provided for LXEO stocks is “Buy” according to the report published on June 06th, 2024.
Stifel gave a rating of “Buy” to LXEO, setting the target price at $20 in the report published on November 28th of the previous year.
LXEO Trading at -37.09% from the 50-Day Moving Average
After a stumble in the market that brought LXEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.74% of loss for the given period.
Volatility was left at 11.78%, however, over the last 30 days, the volatility rate increased by 15.38%, as shares sank -31.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.55% lower at present.
During the last 5 trading sessions, LXEO fell by -32.01%, which changed the moving average for the period of 200-days by -67.52% in comparison to the 20-day moving average, which settled at $5.22. In addition, Lexeo Therapeutics Inc saw -39.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXEO starting from Townsend Richard Nolan, who sale 2,500 shares at the price of $8.20 back on Dec 10 ’24. After this action, Townsend Richard Nolan now owns 120,695 shares of Lexeo Therapeutics Inc, valued at $20,491 using the latest closing price.
Richard Nolan Townsend, the Director of Lexeo Therapeutics Inc, proposed sale 2,500 shares at $8.24 during a trade that took place back on Dec 10 ’24, which means that Richard Nolan Townsend is holding shares at $20,600 based on the most recent closing price.
Stock Fundamentals for LXEO
The total capital return value is set at -0.63. Equity return is now at value -107.21, with -75.77 for asset returns.
Based on Lexeo Therapeutics Inc (LXEO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.42. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -594.64.
Currently, EBITDA for the company is -66.67 million with net debt to EBITDA at 1.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.95.
Conclusion
To sum up, Lexeo Therapeutics Inc (LXEO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
